Vaccine candidate discovery for the next generation of malaria vaccines

Immunology

Volumn 152, Issue 2, 2017, Pages 195-206

  Tuju, James ^a,b   Kamuyu, Gathoni ^a   Murungi, Linda M ^a   Osier, Faith H A ^a,b,c  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b PWANI UNIVERSITY   (Kenya)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

antibodies; bioinformatics; Plasmodium falciparum; vaccines

Indexed keywords

DNA ANTIBODY; DNA VACCINE; MALARIA VACCINE; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

ANTIGEN EXPRESSION; DNA LIBRARY; DNA SCREENING; GENE EXPRESSION; GENE FREQUENCY; GENETIC DRIFT; GENETIC IMMUNIZATION; HUMAN; MALARIA FALCIPARUM; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FUNCTION; PROTEOMICS; REVIEW; VACCINATION; VALIDATION STUDY; ANIMAL; DRUG DEVELOPMENT; GENE LIBRARY; GENETICS; HIGH THROUGHPUT SCREENING; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MALARIA, FALCIPARUM; PARASITOLOGY; PLASMODIUM FALCIPARUM; PROCEDURES;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DRUG DISCOVERY; GENE LIBRARY; HIGH-THROUGHPUT SCREENING ASSAYS; HOST-PATHOGEN INTERACTIONS; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTEOMICS;

EID: 85028945984     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12780     Document Type: Review

References (117)

1. WHO, Chan M. 2016. World Malaria report.
2. Strode C, Donegan S, Garner P, Enayati AA, Hemingway J. The impact of pyrethroid resistance on the efficacy of insecticide-treated bed nets against African Anopheline mosquitoes: systematic review and meta-analysis. PLoS Med 2014; 11:e1001619.
3. Hemingway J. The role of vector control in stopping the transmission of malaria: threats and opportunities. Philos Trans R Soc Lond B Biol Sci 2014; 369:20130431.
4. Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med 2016; 374:2453–64.
5. Cohen JM, Smith DL, Cotter C, Ward A, Yamey G, Sabot OJ et al. Malaria resurgence: a systematic review and assessment of its causes. Malar J 2012; 11:122.
6. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F et al. A research agenda to underpin malaria eradication. PLoS Med 2011; 8:e1000406.
7. Medicines Agency E. (2015). First malaria vaccine receives positive scientific opinion from EMA.
8. Gosling R, von Seidlein L. The future of the RTS, S/AS01 malaria vaccine: an alternative development plan. PLoS Med 2016; 13:1–6.
9. White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B et al. Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis 2015; 15:1450–8.
10. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002; 419:498–511.
11. Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192:733–7.
12. Fowkes FJI, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med 2010; 7:e1000218.
13. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol 2006; 28:51–60.
14. Proietti C, Doolan DL. The case for a rational genome-based vaccine against malaria. Front Microbiol 2015; 6:1–19.
15. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000; 3:445–50.
16. Hiller NL, Bhattacharjee S, van Ooij C, Liolios K, Harrison T, Lopez-Estraño C et al. A host-targeting signal in virulence proteins reveals a secretome in malarial infection. Science 2004; 306:1934–7.
17. Marti M, Good RT, Rug M, Knuepfer E, Cowman AF. Targeting malaria virulence and remodeling proteins to the host erythrocyte. Science 2004; 306:1930–3.
18. Sargeant T, Marti M, Caler E, Carlton J, Simpson K, Speed T et al. Lineage-specific expansion of proteins exported to erythrocytes in malaria parasites. Genome Biol 2006; 7:R12.
19. Thompson J, Janse CJ, Waters AP. Comparative genomics in Plasmodium: a tool for the identification of genes and functional analysis. Mol Biochem Parasitol 2001; 118:147–54.
20. van Dijk MR, Janse CJ, Thompson J, Waters AP, Braks JA, Dodemont HJ et al. A central role for P48/45 in malaria parasite male gamete fertility. Cell 2001; 104:153–64.
21. Weedall GD, Conway DJ. Detecting signatures of balancing selection to identify targets of anti-parasite immunity. Trends Parasitol 2010; 26:363–9.
22. Amambua-Ngwa A, Tetteh KKA, Manske M, Gomez-Escobar N, Stewart LB, Deerhake ME et al. Population genomic scan for candidate signatures of balancing selection to guide antigen characterization in malaria parasites. PLoS Genet 2012; 8:e1002992.
23. Ochola LI, Tetteh KKA, Stewart LB, Riitho V, Marsh K, Conway DJ. Allele frequency-based and polymorphism-versus-divergence indices of balancing selection in a new filtered set of polymorphic genes in Plasmodium falciparum. Mol Biol Evol 2010; 27:2344–51.
24. Tetteh KKA, Osier FHA, Salanti A, Drought L, Failly M, Martin C et al. Analysis of antibodies to newly described Plasmodium falciparum merozoite antigens supports MSPDBL2 as a predicted target of naturally acquired immunity. Infect. Immun. 2013; 81:3835–42.
25. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1–2b trial in Papua New Guinea. J Infect Dis 2002; 185:820–7.
26. Foth BJ, Zhang N, Chaal BK, Sze SK, Preiser PR, Bozdech Z. Quantitative time-course profiling of parasite and host cell proteins in the human malaria parasite Plasmodium falciparum. Mol Cell Proteomics 2012; 11:M111.010645:1–12.
27. Bozdech Z, Llinás M, Pulliam BL, Wong ED, Zhu J, DeRisi JL. The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol 2003; 1:e5.
28. Le Roch KG, Zhou Y, Blair PL, Grainger M, Moch JK, Haynes JD et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 2003; 301:1503–8.
29. Ponts ND, Chung WD, Le Roch KG. Strand-specific RNA-seq applied to malaria samples. In: Clifton NJ, ed. Methods in molecular biology vol. 883. Humana Press, Totowa, NJ, 2012:59–73.
30. Haddad D, Bilcikova E, Witney AA, Carlton JM, White CE, Blair PL et al. Novel antigen identification method for discovery of protective malaria antigens by rapid testing of DNA vaccines encoding exons from the parasite genome. Infect Immun 2004; 72:1594–602.
31. Villard V, Agak GW, Frank G, Jafarshad A, Servis C, Nébié I et al. Rapid identification of malaria vaccine candidates based on α-helical coiled coil protein motif. PLoS One 2007; 2:e645:1–8.
32. Olugbile S, Villard V, Bertholet S, Jafarshad A, Kulangara C, Roussilhon C et al. Malaria vaccine candidate: design of a multivalent subunit α-helical coiled coil poly-epitope. Vaccine 2011; 29:7090–9.
33. Rodríguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, Mora M et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006; 24:191–7.
34. Bensi G, Mora M, Tuscano G, Biagini M, Chiarot E, Bombaci M et al. Multi high-throughput approach for highly selective identification of vaccine candidates: the group A streptococcus case. Mol Cell Proteomics 2012; 11:M111.015693.
35. Zhang X. Detergents: friends not foes for high-performance membrane proteomics toward precision medicine. Proteomics 2017; 17:1600209.
36. Orwick-Rydmark M, Arnold T, Linke D. The Use of Detergents to Purify Membrane Proteins. In Chiu M, ed. Current Protocols in Protein Science Vol. 84. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2016:4.8.1–8.35.
37. Gelhaus C, Fritsch J, Krause E, Leippe M. Fractionation and identification of proteins by 2-DE and MS: towards a proteomic analysis of Plasmodium falciparum. Proteomics 2005; 5:4213–22.
38. Sanders PR, Gilson PR, Cantin GT, Greenbaum DC, Nebl T, Carucci DJ et al. Distinct protein classes including novel merozoite surface antigens in RAFT-like membranes of Plasmodium falciparum. J Biol Chem 2005; 280:40169–76.
39. Swearingen KE, Lindner SE, Shi L, Shears MJ, Harupa A, Hopp CS et al. Interrogating the Plasmodium sporozoite surface: identification of surface-exposed proteins and demonstration of glycosylation on CSP and TRAP by mass spectrometry-based proteomics. PLoS Pathog 2016; 12:1–32.
40. Lindner SE, Swearingen KE, Harupa A, Vaughan AM, Sinnis P, Moritz RL et al. Total and putative surface proteomics of malaria parasite salivary gland sporozoites. Mol Cell Proteomics 2013; 12:1127–43.
41. Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJI et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol 2013; 191:795–809.
42. Osier FH, Mackinnon MJ, Crosnier C, Fegan G, Kamuyu G, Wanaguru M et al. New antigens for a multicomponent blood-stage malaria vaccine. Sci Transl Med 2014; 6:247ra102.
43. Florens L, Liu X, Wang Y, Yang S, Schwartz O, Peglar M et al. Proteomics approach reveals novel proteins on the surface of malaria-infected erythrocytes. Mol Biochem Parasitol 2004; 135:1–11.
44. Stanley HA, Howard RF, Reese RT. Recognition of a Mr 56K glycoprotein on the surface of Plasmodium falciparum merozoites by mouse monoclonal antibodies. J Immunol 1985; 134:3439–44.
45. Holder AA, Freeman RR. Biosynthesis and processing of a Plasmodium falciparum schizont antigen recognized by immune serum and a monoclonal antibody. J Exp Med 1982; 156:1528–38.
46. Deans JA, Alderson T, Thomas AW, Mitchell GH, Lennox ES, Cohen S. Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. Clin Exp Immunol 1982; 49:297–309.
47. Oeuvray C, Bouharoun-Tayoun H, Grass-Masse H, Lepers JP, Ralamboranto L, Tartar A et al. A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Mem Inst Oswaldo Cruz 1994; 89(Suppl 2):77–80.
48. Ranjan R, Chugh M, Kumar S, Singh S, Kanodia S, Hossain MJ et al. Proteome analysis reveals a large merozoite surface protein-1 associated complex on the Plasmodium falciparum merozoite surface. J Proteome Res 2011; 10:680–91.
49. Hsu C-A, Lin W-R, Li J-C, Liu Y-L, Tseng Y-T, Chang C-M et al. Immunoproteomic identification of the hypothetical protein NMB1468 as a novel lipoprotein ubiquitous in Neisseria meningitidis with vaccine potential. Proteomics 2008; 8:2115–25.
50. Connolly JP, Comerci D, Alefantis TG, Walz A, Quan M, Chafin R et al. Proteomic analysis of Brucella abortus cell envelope and identification of immunogenic candidate proteins for vaccine development. Proteomics 2006; 6:3767–80.
51. Schmidt-Ullrich R, Wallach DF. Plasmodium knowlesi-induced antigens in membranes of parasitized rhesus monkey erythrocytes. Proc Natl Acad Sci USA 1978; 75:4949–53.
52. Fontaine A, Pophillat M, Bourdon S, Villard C, Belghazi M, Fourquet P et al. Specific antibody responses against membrane proteins of erythrocytes infected by Plasmodium falciparum of individuals briefly exposed to malaria. Malar J 2010; 9:276.
53. Peng K, Goh YS, Siau A, Franetich J-F, Chia WN, Ong ASM et al. Breadth of humoral response and antigenic targets of sporozoite-inhibitory antibodies associated with sterile protection induced by controlled human malaria infection. Cell Microbiol 2016; 18:1739–50.
54. Cochrane AH, Santoro F, Nussenzweig V, Gwadz RW, Nussenzweig RS. Monoclonal antibodies identify the protective antigens of sporozoites of Plasmodium knowlesi. Proc Natl Acad Sci USA 1982; 79:5651–5.
55. Ellis J, Ozaki LS, Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS et al. Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature 1983; 302:536–8.
56. Guerin-Marchand C, Druilhe P, Galey B, Londono A, Patarapotikul J, Beaudoin RL et al. A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature 1987; 329:164–7.
57. Moyano EM, González LM, Arahuetes S, Benito A. Liver stage antigen 3 isolated from a cDNA library of Plasmodium falciparum erythrocytic stages. Parasitol Res 2007; 102:111–5.
58. Fidock DA, Bottius E, Brahimi K, Moelans II, Aikawa M, Konings RN et al. Cloning and characterization of a novel Plasmodium falciparum sporozoite surface antigen, STARP. Mol Biochem Parasitol 1994; 64:219–32.
59. Coppel RL, Favaloro JM, Crewther PE, Burkot TR, Bianco AE, Stahl HD et al. A blood stage antigen of Plasmodium falciparum shares determinants with the sporozoite coat protein. Proc Natl Acad Sci USA 1985; 82:5121–5.
60. Day KP, Karamalis F, Thompson J, Barnes DA, Peterson C, Brown H, Brown GV, Kemp DJ. Genes necessary for expression of a virulence determinant and for transmission of Plasmodium falciparum are located on a 0.3-megabase region of chromosome 9. Proc Natl Acad Sci USA 1993; 90:8292–6.
61. Borre MB, Dziegiel M, Høgh B, Petersen E, Rieneck K, Riley E et al. Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. Mol Biochem Parasitol 1991; 49:119–31.
62. Raj DK, Nixon CP, Nixon CE, Dvorin JD, DiPetrillo CG, Pond-Tor S et al. Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection. Science 2014; 344:871–7.
63. Birkholtz L-M, Blatch G, Coetzer TL, Hoppe HC, Human E, Morris EJ et al. Heterologous expression of plasmodial proteins for structural studies and functional annotation. Malar J 2008; 7:197.
64. Rappuoli R, Bottomley MJ, D'Oro U, Finco O, De Gregorio E. Reverse vaccinology 2·0: human immunology instructs vaccine antigen design. J Exp Med 2016; 213:469–81.
65. Kabanova A, Perez L, Lilleri D, Marcandalli J, Agatic G, Becattini S et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci 2014; 111:17965–70.
66. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 2010; 84:1005–13.
67. Lilja AE, Mason PW. The next generation recombinant human cytomegalovirus vaccine candidates—beyond gB. Vaccine 2012; 30:6980–90.
68. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013; 31:705–42.
69. Murungi LM, Sondén K, Llewellyn D, Rono J, Guleid F, Williams AR et al. Targets and mechanisms associated with protection from severe Plasmodium falciparum malaria in Kenyan children. Infect Immun 2016; 84:950–63.
70. Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS et al. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med 2014; 12:108.
71. Joos C, Marrama L, Polson HEJ, Corre S, Diatta A-M, Diouf B et al. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One 2010; 5:e9871.
72. Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspeling-Jones H et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity 2015; 42:580–90.
73. Duncan CJA, Hill AVS, Ellis RD. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother 2012; 8:706–14.
74. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995; 182:409–18.
75. Hill DL, Eriksson EM, Schofield L. High yield purification of Plasmodium falciparum merozoites for use in opsonizing antibody assays. J Vis Exp 2014; 89 :e51590, 1–11.
76. Tan J, Pieper K, Piccoli L, Abdi A, Foglierini M, Geiger R et al. A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens. Nature 2015; 529:105–9.
77. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med 1998; 4:358–60.
78. Barfod L, Bernasconi NL, Dahlbäck M, Jarrossay D, Andersen PH, Salanti A et al. Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA. Mol Microbiol 2007; 63:335–47.
79. Ricke CH, Staalsoe T, Koram K, Akanmori BD, Riley EM, Theander TG et al. Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A. J Immunol 2000; 165:3309–16.
80. Salanti A, Dahlbäck M, Turner L, Nielsen MA, Barfod L, Magistrado P et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 2004; 200:1197–203.
81. Duffy PE, Fried M. Antibodies that inhibit Plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns. Infect Immun 2003; 71:6620–3.
82. Staalsoe T, Shulman CE, Bulmer JN, Kawuondo K, Marsh K, Hviid L. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet 2004; 363:283–9.
83. Escolano A, Dosenovic P, Nussenzweig MC. Progress toward active or passive HIV-1 vaccination. J Exp Med 2017; 214:3–16.
84. Jaworski JP, Vendrell A, Chiavenna SM. Neutralizing monoclonal antibodies to fight HIV-1: on the threshold of success. Front Immunol 2016; 7:661.
85. Mehlin C, Boni E, Buckner FS, Engel L, Feist T, Gelb MH et al. Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol 2006; 148:144–60.
86. Aguiar JC, LaBaer J, Blair PL, Shamailova VY, Koundinya M, Russell JA et al. High-throughput generation of P. falciparum functional molecules by recombinational cloning. Genome Res 2004; 14:2076–82.
87. Vedadi M, Lew J, Artz J, Amani M, Zhao Y, Dong A et al. Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol Biochem Parasitol 2007; 151:100–10.
88. Carrió MM, Villaverde A. Construction and deconstruction of bacterial inclusion bodies. J Biotechnol 2002; 96:3–12.
89. Tsuboi T, Takeo S, Iriko H, Jin L, Tsuchimochi M, Matsuda S et al. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect Immun 2008; 76:1702–8.
90. Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, Valdez C et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008; 8:4680.
91. Kwon Y-C, Jewett MC, Choi CY, Yokoyama S, Swartz JR. High-throughput preparation methods of crude extract for robust cell-free protein synthesis. Sci Rep 2015; 5:8663.
92. Arumugam TU, Takeo S, Yamasaki T, Thonkukiatkul A, Miura K, Otsuki H et al. Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen. Infect Immun 2011; 79:4523–32.
93. Cile Crosnier C, Wanaguru M, Mcdade B, Osier FH, Marsh K, Rayner JC et al. A library of functional recombinant cell-surface and secreted P. falciparum merozoite proteins. Mol Cell Proteomics 2013; 12:3976–86.
94. Caruana EJ, Roman M, Hernández-Sánchez J, Solli P. Longitudinal studies. J Thorac Dis 2015; 7:E537–40.
95. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg 1989; 83:293–303.
96. Kinyanjui SM, Bejon P, Osier FH, Bull PC, Marsh K. What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity. Malar J 2009; 8:242.
97. Nkumama IN, O'Meara WP, Osier FHA. Changes in malaria epidemiology in Africa and new challenges for elimination. Trends Parasitol 2017; 33:128–40.
98. Conway DJ. Natural selection on polymorphic malaria antigens and the search for a vaccine. Parasitol Today 1997; 13:26–9.
99. Teo A, Feng G, Brown GV, Beeson JG, Rogerson SJ. Functional antibodies and protection against blood-stage malaria. Trends Parasitol 2016; 32:887–98.
100. Good MF, Hawkes MT, Yanow SK. Humanized mouse models to study cell-mediated immune responses to liver-stage malaria vaccines. Trends Parasitol 2015; 31:583–94.
101. Hayton K, Gaur D, Liu A, Takahashi J, Henschen B, Singh S et al. Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe 2008; 4:40–51.
102. Wanaguru M, Liu W, Hahn BH, Rayner JC, Wright GJ. RH5–Basigin interaction plays a major role in the host tropism of Plasmodium falciparum. Proc Natl Acad Sci 2013; 110:20735–40.
103. Trieu A, Kayala MA, Burk C, Molina DM, Freilich DA, Richie TL et al. Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Mol Cell Proteomics 2011; 10(M111):007948.
104. Mordmüller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 2017; 542:445–9.
105. Rener J, Graves PM, Carter R, Williams JL, Burkot TR. Target antigens of transmission-blocking immunity on gametes of Plasmodium falciparum. J Exp Med 1983; 158:976–81.
106. Camus D, Hadley TJ. A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science 1985; 230:553–6.
107. Delplace P, Fortier B, Tronchin G, Dubremetz JF, Vernes A. Localization, biosynthesis, processing and isolation of a major 126 kDa antigen of the parasitophorous vacuole of Plasmodium falciparum. Mol Biochem Parasitol 1987; 23:193–201.
108. Robson KJH, Hall JRS, Jennings MW, Harris TJR, Marsh K, Newbold CI et al. A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 1988; 335:79–82.
109. Marchand C, Druilhe P. How to select Plasmodium falciparum pre-erythrocytic antigens in an expression library without defined probe. Bull World Health Organ 1990; 68(Suppl):158–64.
110. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994; 84:1594–602.
111. Salanti A, Staalsoe T, Lavstsen T, Jensen ATR, Sowa MPK, Arnot DE et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol 2003; 49:179–91.
112. Kariu T, Ishino T, Yano K, Chinzei Y, Yuda M. CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. Mol Microbiol 2006; 59:1369–79.
113. Olugbile S, Kulangara C, Bang G, Bertholet S, Suzarte E, Villard V et al. Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c. Infect Immun 2009; 77:5701–9.
114. Coppel RL, Cowman AF, Anders RF, Bianco AE, Saint RB, Lingelbach KR et al. Immune sera recognize on erythrocytes Plasmodium falciparum antigen composed of repeated amino acid sequences. Nature 1984; 310:789–92.
115. Koenen M, Scherf A, Mercereau O, Langsley G, Sibilli L, Dubois P et al. Human antisera detect a Plasmodium falciparum genomic clone encoding a nonapeptide repeat. Nature 1984; 311:382–5.
116. Vermeulen AN, Roeffen WF, Henderik JB, Ponnudurai T, Beckers PJ, Meuwissen JH. Plasmodium falciparum transmission blocking monoclonal antibodies recognize monovalently expressed epitopes. Dev Biol Stand 1985; 62:91–7.
117. Moelans II, Meis JF, Kocken C, Konings RN, Schoenmakers JG. A novel protein antigen of the malaria parasite Plasmodium falciparum, located on the surface of gametes and sporozoites. Mol Biochem Parasitol 1991; 45:193–204.